3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
6
Phase 1
3
Phase 2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
2
Thoracic
1
Conditions
Pancreatic Neoplasms
54
Carcinoma, Non-Small-Cell Lung
22
Neoplasms
17
Neoplasm Metastasis
16
Breast Neoplasms
16
Triple Negative Breast Neoplasms
10
Colorectal Neoplasms
9
Stomach Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Ovarian Neoplasms
6
Melanoma
5
Carcinoma, Pancreatic Ductal
5
Adenocarcinoma
5
Small Cell Lung Carcinoma
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Hepatocellular
4
Rectal Neoplasms
3
Peritoneal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Hodgkin Disease
3
Fallopian Tube Neoplasms
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Solid Tumor
2
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Ductal Adenocarcinoma
2
Nasopharyngeal Carcinoma
2
Interventions
pembrolizumab
23
Carboplatin
6
Pemetrexed
5
Paclitaxel
4
Cisplatin
4
130-nm albumin-bound paclitaxel
3
spartalizumab
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Axitinib
2
Albumin-Bound Paclitaxel
2
trametinib
1
ribociclib
1
osimertinib
1
lenvatinib
1
etoposide phosphate
1
durvalumab
1
dabrafenib
1
cemiplimab
1
binimetinib
1
Vascular Endothelial Growth Factor A
1
Nivolumab
1
Gemcitabine
1
Etoposide
1
Doxorubicin
1
Docetaxel
1
DS-8273a
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT05017012
2026-03-27
MK-3475A-C18
Merck Sharp & Dohme LLC
Phase 1
Active not recruiting
72 enrolled
NCT03396445
2025-11-05
MK-5890-001
Merck Sharp & Dohme LLC
Phase 1
Completed
182 enrolled
36 charts
NCT02622074
2020-09-10
KEYNOTE 173
Merck Sharp & Dohme LLC
Phase 1
Completed
60 enrolled
26 charts